l carnitine hyperammonemia Science review: in the treatment of valproic acid-induced toxicity – what is the evidence? | Critical Care Hepatic Encephalopathy: Current and Emerging

The half-maximal inhibitory concentrations (IC 50 ) values of sorafenib-resistant SK-Hep1 (SK-SR) and sorafenib-resistant HepG2 (HepG2-SR) were 17.14 M and 16.05 M respectively which were notably higher than that of parental cells (Fig

A severe carnitine deficiency is thought to contribute to VHE.[5] Although the precise mechanism leading to hypocarnitinemia in patients treated with valproate is not known, a previous clinical study showed a significant decrease in carnitine concentration and changes in the ratio of acylcarnitine to free carnitine for both neurological and psychiatric indications.[6] Recently, we reported that VPA treatment induces hyperammonemia and causes concentration-dependent carnitine deficiency regardless of the use of additional mood stabilizers, while serum levels of NH3 do not correlate with VPA concentrations in psychiatric patients.[7] In the field of pediatric neurology, reports suggests carnitine supplementation tends to normalize elevated NH3 concentration by binding to VPA and relieving the inhibition of urea synthesis with favorable clinical response.[8,9] In contrast, despite the widespread use of VPA in psychiatry, carnitine supplementation for the treatment of hyperammonemia and hypocarnitinemia has not been prospectively studied in a psychiatric setting

Ultra-processed foods also contain emulsifiers, artificial sweeteners, and other additives that have been shown in research to degrade tight junction integrity and reduce microbial diversity independently of their effects on fiber content

& Williamson, J

Midazolam-resistant seizures and brain injury after acute intoxication of diisopropylfluorophosphate, an organophosphate pesticide and surrogate for nerve agents

Aging Cell 11 , 867875 (2012)